Stem cell infusion aims to buy time for kids with fatal brain disease
NCT ID NCT06030648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether a single infusion of donated mesenchymal stem cells is safe for children with cerebral adrenoleukodystrophy (cALD), a rare and life-threatening brain disease. The stem cells are given as a temporary bridge to buy time before a more definitive treatment like a bone marrow transplant or gene therapy. Only 10 participants are being enrolled, and the main goal is to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mesenchymal stem cells (MSC)
- What this could lead to
- If it works, this could provide a safe way to stabilize brain inflammation in children with cerebral adrenoleukodystrophy while they wait for a stem cell transplant or gene therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so it is primarily checking safety, not effectiveness. The study is currently suspended, and the treatment is only a temporary bridge, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL ADRENOLEUKODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.